Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2015 | iwNHL 2015 roundtable: Immune checkpoint blockade for non-Hodgkin lymphoma

Anas Younes, John Gribben, Nathan Fowler and Stephen Ansell • 3 Oct 2015
iwNHL 2015
Non-Hodgkin Lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, John Gribben, MD, DSc, FRCPath, FRCP FMedSci, of Barts and The London School of Medicine and Dentistry, London, UK, chairs a discussion with Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, Stephen M. Ansell, MD, PhD, of Mayo Clinic, Rochester, MN, and Nathan H. Fowler, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, on emerging immune targets, such as the interaction between programmed death ligand-1 (PD-L1) and programmed cell death-1 (PD-1), that are demonstrating clinical responses with the use of immune checkpoint inhibitors in patients with non-Hodgkin lymphoma.

More from Anas Younes

1:01
Fimepinostat with venetoclax in R/R lymphoma
Anas Younes • 7 Dec 2019
1:27
Atezolizumab plus R-CHOP in DLBCL: encouraging results
Anas Younes • 7 Dec 2019
1:42
Dual inhibition of BCL2 and MCL1 using tumor targeted nanoparticles in lymphoma
Anas Younes • 7 Dec 2019
2:55
Ibrutinib in combination with R-CHOP in DLBCL: does age make a difference?
Anas Younes • 6 Dec 2018

More from John Gribben

2:42
Investigating the treatment preferences of physicians in R/R follicular lymphoma
John Gribben • 9 Dec 2023
1:20
Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort
John Gribben • 9 Dec 2023
1:04
The future of CLL therapy
John Gribben • 9 Dec 2023
Novel therapies in NHL: antibody-drug conjugates
Andrew Davies et al. • 17 Oct 2023

More from Nathan Fowler

1:36
ELARA: Tisa-cel in follicular lymphoma
Nathan Fowler • 12 Dec 2021
0:39
10 year follow up of rituximab and lenalidomide in low tumor burden FL
Nathan Fowler • 12 Dec 2021
1:03
RELEVANCE: Rituximab and lenalidomide in FL
Nathan Fowler • 12 Dec 2021
3:44
ELARA: tisa-cel in R/R follicular lymphoma
Nathan Fowler • 18 Jun 2021

More from Stephen Ansell

MBL: biology, classification & the possibility of early interception
Andrew Rawstron et al. • 25 Mar 2024
1:03
What’s on the horizon for Hodgkin lymphoma?
Stephen Ansell • 11 Dec 2023
0:51
Treating patients with Hodgkin lymphoma who are chemo-resistant
Stephen Ansell • 11 Dec 2023
1:21
Hodgkin lymphoma highlights from ASH 2023: nivo-AVD versus BV-AVD in patients with HL
Stephen Ansell • 11 Dec 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals